Provided by Tiger Trade Technology Pte. Ltd.

Gilead Sciences

146.08
-0.7750-0.53%
Volume:1.93M
Turnover:280.57M
Market Cap:181.23B
PE:-55.86
High:147.23
Open:146.73
Low:144.65
Close:146.85
52wk High:157.29
52wk Low:114.02
Shares:1.24B
Float Shares:1.24B
Volume Ratio:0.60
T/O Rate:0.16%
Dividend:3.22
Dividend Rate:2.20%
EPS(TTM):-2.6150
EPS(LYR):6.78
ROE:-20.68%
ROA:14.09%
PB:15.32
PE(LYR):21.54

Loading ...

RBC Capital Adjusts Gilead Sciences Price Target to $123 From $120, Maintains Sector Perform Rating

MT Newswires Live
·
Aug 05

Immuneering Expects Cash Runway to Fund Operations into 2029

Reuters
·
Aug 05

Kymera Therapeutics Q2 Collaboration Revenue More than Doubles, Beats Estimates

Reuters
·
Aug 05

Gilead : Leerink Partners Raises Target Price to $130 from $126

THOMSON REUTERS
·
Aug 05

Gilead Sciences (GILD) Gets a Buy from Wells Fargo

TIPRANKS
·
Aug 05

Gilead Buy Rating Reaffirmed on Strong HIV-Driven Growth and Raised Revenue Outlook; $170 Price Target Maintained

TIPRANKS
·
Aug 05

Street View: Gilead's HIV Strength Outshines Long-Term Competitive Worries

Reuters
·
Aug 05

U.S. Research Roundup-Ametek, Ball Corp, McDonald's

Reuters
·
Aug 05

Switzerland's Sandoz H1 Net Sales Rise on Biosimilar Growth

Reuters
·
Aug 05

Gilead : Truist Securities Cuts Target Price to $150 from $156

THOMSON REUTERS
·
Aug 05

Gilead Corrects Q2 2026 Europe Odefsey Sales to $58 Million

Reuters
·
Aug 05

Dow Jones Top Company Headlines at 7 PM ET: SpaceX Revenue Could Reach $1 Trillion, Elon Musk Says | Paramount's ...

Dow Jones
·
Aug 05

Gilead Forecasts FY26 Yeztugo Revenue at About $1 Billion

Reuters
·
Aug 05

Gilead CEO Daniel O’Day Sells 15,000 Common Shares Worth $1.96 Million

Reuters
·
Aug 05

Gilead Says Q2 2026 Revenue Growth is Driven by Biktarvy, Descovy and Yeztugo Demand, Pricing Gains

Reuters
·
Aug 05

Gilead Sciences Posts Net Loss as R&D Costs from Acquisitions Weigh on HIV Drug Revenue Growth

Deep News
·
Aug 05

Gilead Sciences, Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

Gilead Exec Says Saw a Softer Hiv Treatment Market in Q2 as People Fell Out of Insurance Plans Due to Eliminated Aca Tax Subsidies - Conf Call

THOMSON REUTERS
·
Aug 05

Gilead Exec Says Raising Full Year Hiv Growth Expectations to 9%-10% Year-over-Year from Prior Guidance of 8% Growth - Conf Call

THOMSON REUTERS
·
Aug 05

Gilead Exec Says Launch Preparations Fully Underway for Anito-Cel Cell Therapy, with Five Months to Go Until FDA Pdufa Date - Conf Call

THOMSON REUTERS
·
Aug 05